Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvain Ladoire

Showing results (91-100 of 167) with videos related to

Pageof 17
Sort By:
Frontiers in Oncology|January 26, 2024
Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapySilvia Mihaela Ilie, Nathalie Briot, Guillaume Constatin, et al.
Breast Cancer Research : BCR|November 19, 2022
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancersElise Ballot, Loïck Galland, Hugo Mananet, et al.
British Journal of Cancer|January 21, 2021
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trialLuc Cabel, Frédérique Berger, Paul Cottu, et al.
Annals of Surgical Oncology|January 15, 2014
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resectionFrancois Ghiringhelli, Damien Bichard, Samuel Limat, et al.
Cancer Research|August 7, 2016
Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment RegimenEmeric Limagne, Romain Euvrard, Marion Thibaudin, et al.
Autophagy|June 1, 2012
Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimensSylvain Ladoire, Kariman Chaba, Isabelle Martins, et al.
European Urology Oncology|June 1, 2024
Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic ReviewMichael Baboudjian, Arthur Peyrottes, Charles Dariane, et al.
Bulletin Du Cancer|November 28, 2021
Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohortHélène Costaz, Delphine Boulle, Aurélie Bertaut, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 23, 2021
Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutationsAnthony Bergeron, Gaëtan MacGrogan, Aurélie Bertaut, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2022
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approachManon Reda, Pauline Macaire, Hélène Bellio, et al.
Pageof 17

Showing results (91-100 of 167) with videos related to

Sort By:
Pageof 17
Frontiers in Oncology|January 26, 2024
Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapySilvia Mihaela Ilie, Nathalie Briot, Guillaume Constatin, et al.
Breast Cancer Research : BCR|November 19, 2022
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancersElise Ballot, Loïck Galland, Hugo Mananet, et al.
British Journal of Cancer|January 21, 2021
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trialLuc Cabel, Frédérique Berger, Paul Cottu, et al.
Annals of Surgical Oncology|January 15, 2014
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resectionFrancois Ghiringhelli, Damien Bichard, Samuel Limat, et al.
Cancer Research|August 7, 2016
Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment RegimenEmeric Limagne, Romain Euvrard, Marion Thibaudin, et al.
Autophagy|June 1, 2012
Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimensSylvain Ladoire, Kariman Chaba, Isabelle Martins, et al.
European Urology Oncology|June 1, 2024
Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic ReviewMichael Baboudjian, Arthur Peyrottes, Charles Dariane, et al.
Bulletin Du Cancer|November 28, 2021
Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohortHélène Costaz, Delphine Boulle, Aurélie Bertaut, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 23, 2021
Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutationsAnthony Bergeron, Gaëtan MacGrogan, Aurélie Bertaut, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2022
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approachManon Reda, Pauline Macaire, Hélène Bellio, et al.
Pageof 17